drugset / Trial / NCT04737122
Study of LM-061 in Subjects in Advanced Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I, open-label, dose escalation study to evaluate the safety, tolerability, PK, and preliminary efficacy of LM-061 in subjects with advanced tumors.
Timeline
- Start
- 2021-05-06
- Primary completion
- 2022-07-19
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LM-061 | Unknown | — | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |